key: cord-284193-qslc2wry
authors: Malek Mahdavi, Aida
title: A brief review of interplay between vitamin D and angiotensin‐converting enzyme 2: Implications for a potential treatment for COVID‐19
date: 2020-06-25
journal: Rev Med Virol
DOI: 10.1002/rmv.2119
sha: 
doc_id: 284193
cord_uid: qslc2wry

The novel coronavirus disease 2019 (COVID‐19) is rapidly expanding and causing many deaths all over the world with the World Health Organization (WHO) declaring a pandemic in March 2020. Current therapeutic options are limited and there is no registered and/or definite treatment or vaccine for this disease or the causative infection, severe acute respiratory coronavirus 2 syndrome (SARS‐CoV‐2). Angiotensin‐converting enzyme 2 (ACE2), a part of the renin‐angiotensin system (RAS), serves as the major entry point into cells for SARS‐CoV‐2 which attaches to human ACE2, thereby reducing the expression of ACE2 and causing lung injury and pneumonia. Vitamin D, a fat‐soluble‐vitamin, is a negative endocrine RAS modulator and inhibits renin expression and generation. It can induce ACE2/Ang‐(1‐7)/MasR axis activity and inhibits renin and the ACE/Ang II/AT1R axis, thereby increasing expression and concentration of ACE2, MasR and Ang‐(1‐7) and having a potential protective role against acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Therefore, targeting the unbalanced RAS and ACE2 down‐regulation with vitamin D in SARS‐CoV‐2 infection is a potential therapeutic approach to combat COVID‐19 and induced ARDS.

pulmonary and rheumatic diseases. 2 This newly emerging disease imposes a lot of negative impacts on the economy and healthcare structures in affected countries. Currently, therapeutic options are limited and there is no registered and/or definite treatment or vaccine for this problem. Alternative solutions to prevent and control this virus are therefore desirable.

Vitamin D is a fat-soluble micronutrient and also a hormone produced in body from sunlight. Besides its function in preserving bone integrity, it has a role in maturation of different cells such as immune cells. 5 Vitamin D deficiency is identified as a global public health matter and numerous investigations have reported that poor vitamin D status can affect a variety of diseases. 6 A majority of healthy individuals have low vitamin D concentration, mainly at the end of the winter. 5 Furthermore, individuals who stay at home or institution as well as night workers and elderly subjects, who have low exposure to sunlight, may suffer from vitamin D deficiency. 6 Since COVID-19 was recognized in winter 2019 and mainly influenced middle-aged and elderly subjects, it has been supposed that virus-infected subjects may not have adequate vitamin D levels. Even though the mechanisms responsible for vitamin D function in the host immune system have been explained, 7, 8 the interplay between viral infections and vitamin D remains a confusing matter, and plausible interactions between viral infections and vitamin D do not appear to be simple.

Angiotensin-converting enzyme 2 (ACE2), a part of the reninangiotensin system (RAS), serves as the major entry point into cells for some coronaviruses such as HCoV-NL63, SARS-CoV and SARS-CoV-2 that cause SARS and COVID-19, respectively. [9] [10] [11] [12] It has also been shown that SARS-CoV-2 attaches to human ACE2 through its spike glycoprotein, thereby reducing the expression of ACE2 and causing lung injury and pneumonia. [12] [13] [14] [15] Therefore, considering the importance of vitamin D in RAS and regulating ACE and ACE2, 16 we supposed that vitamin D could be considered as a potential therapeutic option for this novel coronavirus.

This narrative mini-review has been conducted using an online search on PubMed and Google scholar in order to discuss the potential pathways connecting vitamin D, COVID-19 and its therapy, with a focus on the RAS and ACE2.

Coronaviruses, the viruses with the largest single stranded-RNA genome, belong to the family of Coronaviridae. 17 Coronaviruses cause enzootic diseases in birds and mammals, including humans. 18 Furthermore, the host immune response can be essential for the pathogenesis of clinical features. 19 When the virus binds to the host cells via its target receptor and enters the cells, its antigen will be presented to the antigen presentation cells (APC), which is a central part of the body's anti-viral immunity. Antigen presentation then stimulates the body's humoral and cellular immunity, which are mediated by virusspecific B and T cells. The antibody profile against acute viral infections including SARS-CoV and SARS-CoV-2 has a typical pattern of IgM and IgG production. 20 Moreover, the number of CD4+ and CD8+ T cells decreased significantly in the peripheral blood of infected patients. 20 In addition, the inflammatory response and secretion of cytokines and chemokines, which occurs during acute viral infections like SARS-CoV and SARS-CoV-2 attracts immune cells, particularly monocytes and T lymphocytes from the blood into the infected site. 21 In most subjects, recruited cells clear the infection in the lung, the immune response recedes and patients recover. 21 However, in some patients, a dysfunctional immune response occurs, which triggers a cytokine storm that mediates extensive lung inflammation. 21 ACE2 is a part of the RAS identified in 2000. 22 It is the human homologue of ACE but is different from ACE in substrate specificity. 22 ACE2 is a membrane protein found in nearly all body tissues with relatively higher expression in respiratory epithelial cells, alveolar cells type I and II, heart, kidney, blood vessels and the gastrointestinal tract. 9,23,24 ACE2 catalyzes the cleavage of angiotensin II (Ang II) (a vasoconstrictor peptide) into angiotensin 1-7 [Ang-(1-7)] (a vasodilator), thereby reducing blood pressure. 25 Ang-(1-7) stimulates nitric oxide synthase (NOS) and further antagonizes Ang II activity through its AT1 receptor. 26 It seems that ACE/ACE2 ratio has a considerable impact on various diseases like diabetes, hypertension, and nephropathy. 27 ACE2is also the receptor on host cell surface and the major entry point into cells for some coronaviruses such as HCoV-NL63,

COVID-19. 9-12 SARS-CoV-2 binds to human ACE2 through its spike glycoprotein and reduces ACE2 expression, thereby causing excessive generation of AngII via the enzyme ACE. Ang II has been demonstrated to stimulate cell growth and proliferation of lung fibroblasts 28, 29 and up-regulates the expression of transforming growth factor-β (TGF-β), 30 a central player in fibrogenesis that is associated with the differentiation of fibroblast to myofibroblasts, which dramatically increases extracellular matrix protein deposition. 31 Ang II is involved in lung inflammation through the generation of reactive oxygen species and the release of proinflammatory cytokines. 32, 33 Ang II has been shown to induce alveolar epithelial cell apoptosis, 34 which is believed to initiate the fibrotic process and is also involved in promoting procoagulatory effects through activating plasminogen activator inhibitor-1. 35 Induction of type 1a Ang II receptor (AGTR1A) enhances pulmonary vascular permeability, thereby causing lung injury and pneumonia; this possibly explains the lung damage following decreasing ACE2 expression. [12] [13] [14] [15] In an animal study of ARDS, ACE2 knockout mice exhibited intense lung disease, characterized by increases in vascular permeability and lung edema. 36 Also, ACE2 overexpression decreased lipopolysaccharide (LPS)-induced ARDS through the Ang-(1-7)/Mas pathway by suppressing extracellular signal-regulated kinase/nuclear factor-κB (NF-κB) activation. 37 Increase in the ACE/ACE2 ratio that occurs during COVID-19 presumably affects kidney damage initiation. 26 Meanwhile, ACE2 affects biologic peptides outside the RAS such as the Kinin-Kallikrein system, Apelin-13 and dynorphin A peptide. These peptides can be elevated and impose unfavorable effects by attenuatingACE2 expression. 38 Furthermore, ACE2 hydrolyzes the active bradykinin metabolite DABK (desArg 9 -bradykinin). 39 A decreased activity of ACE2 impairs the inactivation of DABK and therefore, enhances its signaling through bradykinin B1 receptor (BKB1R). As a consequence, fluid extravasation and leukocyte recruitment to the lung occur. 40 55, 56 Compared to subjects with sufficient 25(OH)D levels (≥30 ng/mL), those with insufficiency (15-29.9 ng/mL) and deficiency (<15 ng/mL) had higher circulating Ang II concentrations. Furthermore, those with vitamin D deficiency had significantly blunted renal plasma flow responses to infused Ang II. 57 Since there is no clear definition regarding the optimal concentration of vitamin D to use in different clinical settings including patients with COVID-19, so this fact may impact its interaction with ACE2 in COVID-19. Persistent deficiency in vitamin D level may activate the RAS, thereby leading to chronic CVD and decreased lung function as well as inducing RAS activation lung fibrosis. 58 Patients with these comorbidities account for a higher proportion of critically ill cases in COVID-19. 58 The COVID-19 infection becomes more severe especially in elderly, hypertensive, diabetic and obese patients and smokers. 59 Particularly in the presence of diabetes mellitus and accompanying comorbid conditions such as hypertension, obesity, old age and smoking, cytosolic pH is low, thus the virus easily may enter the cell by attaching to ACE2. 60, 61 Especially in elderly patients with diabetes, COVID-19 infection will be more severe since cytosolic pH is lower. 61 Recently, it has been reported that CVD or RAS blockade medications may increase ACE2 levels, augmenting available substrate for SARS-CoV-2 infection. 62 Furthermore, circulating ACE2, shed from endothelial cells is a biomarker of hypertension and heart failure 63 as well as diabetes, 64 reflecting increased ACE2 activity. SARS-CoV-2 infection down-regulates ACE2 activity, resulting in toxic Ang II over-accumulation which in turn may cause ARDS or fulminant myocarditis. 62 In addition, some medications such as antibiotics, anti-inflammatory agents, antihypertensives and endocrine drugs decrease serum 25(OH)D levels via activating the pregnane-X receptor. 65 Medication use usually increases with age. 65 Therefore, normalization of vitamin D concentrations can lower RAS activity by transcriptional suppression of renin expression. 66 Xu et al 54 also showed that vitamin D suppressed renin, ACE and AngII expression and increased ACE2 concentration in LPS-induced ALI. Thus, vitamin D may decrease LPS-induced ALI by inducing ACE2/Ang-(1-7) axis and suppressing renin and the ACE/Ang II/AT1R axis. 54 In another study by Yang et al, 67 1,25(OH)2D3 enhanced mRNA expression of VDR and ACE2 as well as VDR and ACE2 levels in rat models of LPS-induced ALI compared to controls, indicating that increased expression of ACE2 mRNA and VDR mRNA had a role in protection against ALI development. Furthermore, clinical features and pathological changes of lung tissues in the calcitriol-treated LPS rats were remarkably milder than controls. 67 Lin et al 68 observed that calcitriol decreased ACE concentration and ACE/ACE2 ratio and enhanced ACE2 concentration in diabetic rats. In addition, calcitriol treatment remarkably suppressed p38 mitogen-activated protein kinase and extracellular signal-regulated kinase (ERK) phosphorylation, but not c-Jun N-terminal kinases phosphorylation, and effectively weakened ACE upregulation and ACE2 down-regulation. 68 Accordingly, administration of the synthetic vitamin D analog, paricalcitol, led to increased levels of ACE2 in tubular cells and decreased levels of ACE2 within the circulation in an animal model of type I diabetes, thereby slowing the development of diabetic nephropathy. 69 Cui et al 70 production. 70 The proposed potential therapeutic effect of vitamin D for COVID-19 and induced ARDS is summarized in Figure 1 .

While the beneficial effects of vitamin D on COVID-19 infection are mainly from observational studies of disease incidence or prevalence with respect to serum 25(OH)D concentrations, 43 most vitamin D randomized clinical trials have not declared that vitamin D supplementation reduced the risk of non-skeletal disorders. 71, 72 Although it is more likely that any protective effect of vitamin D against COVID-19 is related to suppression of cytokine response and reduced severity/risk for ARDS, there is also evidence from a meta-analysis that regular oral vitamin D2/D3 intake (in doses up to 2000 IU/day) is safe and protective against acute respiratory tract infection, especially in subjects with vitamin D deficiency. 73 Thus, it seems possible that vitamin D prophylaxis (without over-dosing) may decrease the severity of illness caused by SARS-CoV-2, especially in settings where hypovitaminosis D is common. 74 Rhodes et al 75 also indicated that it would be reasonable to consider vitamin D supplementation to protect musculoskeletal health in those at risk of deficiency due to being housebound. Moreover, Marik et al 76 suggested that vitamin D deficiency may partly explain the geographic variations in the reported case fatality rate of COVID-19, indicating that supplementation with vitamin D may reduce the mortality from this pandemic. In addition, significant relationship was observed between vitamin D levels and the number COVID-19 cases and especially the mortality caused by this infection. 77 The most vulnerable group of population for COVID-19 is also the one that has the most deficit in vitamin D. 77 To reduce the risk of infection, it is recommended that individuals at risk of COVID-19 take 10 000 IU/day of vitamin D3 for a few weeks to rapidly increase 25(OH)D levels above 40-60 ng/mL, followed by 5000 IU/day. 43 For treatment of subjects who become infected with COVID-19, higher vitamin D3 doses might be useful. 43 

Taking into account the above-mentioned evidence, it seems that targeting the unbalanced RAS and ACE2 down-regulation with vitamin D in SARS-CoV-2 infection may be a potential therapeutic approach to combat the expanding of COVID-19 and induced ARDS. 

The authors have no competing interest.

https://orcid.org/0000-0003-0176-5438

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Vitamin D insufficiency among free-living healthy young adults

Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease

Vitamin D: nutrient, hormone, and immunomodulator

Impact of vitamin D on immune function: lessons learned from genome-wide analysis

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Coronaviruses: an overview of their replication and pathogenesis

Receptor recognition and cross-species infections of SARS coronavirus

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structure analysis of the receptor binding of 2019-nCoV

Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Molecular mechanism of vitamin D in the cardiovascular system

Bats and coronaviruses

Coronavirus envelope protein: current knowledge

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Molecular immune pathogenesis and diagnosis of COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

A novel angiotensin converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

ACE2 of the heart: from angiotensin I to angiotensin (1-7)

ACE and ACE2 in kidney disease

The discovery of angiotensinconverting enzyme 2 and its role in acute lung injury in mice

Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor

Angiotensin II and the fibroproliferative response to acute lung injury

Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages

Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition

Role of oxidative stress in pulmonary fibrosis

Effects of angiotensin on the expression of fibrosis-associated cytokines, growth factors, and matrix proteins in human lung fibroblasts

Angiotensin II induces apoptosis in human and rat alveolar epithelial cells

Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways

The role of bradykinin in lung ischemia-reperfusion injury in a rat lung transplantation model

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/ BKB1R axis and facilitates LPS-induced neutrophil infiltration

Vitamin D: modulator of the immune system

Evidence that Vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Vitamin D and 1,25(OH)2D regulation of T cells

Letter: COVID-19, and vitamin D. Authors' Reply Aliment PharmacolTher

D3) pre-and post-treatment suppresses inflammatory response to influenza a (H1N1) infection in human lung A549 epithelial cells

Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS)

Vitamin D deficiency and acute lung injury

Vitamin D deficiency: a factor in COVID-19, progression, severity and mortality?-an urgent call for research. Mito Fit Preprint Arch

VDR attenuates acute lung injury by blocking Ang-2-Tie-2 pathway and renin-angiotensin system

Effect of vitamin D deficiency in Korean patients with acute respiratory distress syndrome

The association of vitamin D status with acute respiratory morbidity in preterm infants

Vitamin D/VDR signaling attenuates lipopolysaccharide-induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier

Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system

Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system

Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the reninangiotensin system: the Ludwigshafen risk and cardiovascular health (LURIC) study

Chronic vitamin D deficiency induces lung fibrosis through activation of the renin-angiotensin system

Comment on organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19

Intracellular pH in human and experimental hypertension

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic

Is there an association between COVID-19 mortality and the renin-angiotensin system -a call for epidemiologic investigations

New perspectives in the reninangiotensinaldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure

Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications

Influence of drugs on vitamin D and calcium metabolism

1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter

Effect of Vitamin D on ACE2 and Vitamin D Receptor Expression in Rats with LPS-Induced Acute Lung Injury

Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease

Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria

Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of reninangiotensin system

Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials

Non-skeletal health effects of vitamin D supplementation: a systematic review on findings from meta-analyses summarizing trial data

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

Letter: COVID-19, and vitamin D

Editorial: low population mortality from COVID-19 in countries south of latitude 35 degrees north supports vitamin D as a factor determining severity

Does vitamin D status impact mortality from SARS-CoV-2 infection

How to cite this article: Malek Mahdavi A. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19


